Hematology

The Future of Acquired TTP

August 31st 2021, 1:00pm

Video

X. Long Zheng, MD, PhD, discusses the unmet needs of acquired TTP, and the future of treatment.

Treatment Considerations for Caplacizumab

August 26th 2021, 1:00pm

Video

X. Long Zheng, MD, PhD, explains when physicians should administer caplacizumab after suspecting a diagnosis of acquired TTP, and discusses the risk of relapse or refractory disease.

Using Caplacizumab to Treat Acquired TTP

August 24th 2021, 1:00pm

Video

An expert in acquired TTP describes the use of caplacizumab in treating acquired TTP, and highlights data from a phase III clinical trial.

Treatment Options for Acquired TTP

August 19th 2021, 1:00pm

Video

X. Long Zheng, MD, PhD, details the typical healthcare costs for acquired TTP, the treatment options available to patients, and the goals of the healthcare provider.

Diagnostic Approach to Acquired TTP

August 17th 2021, 1:00pm

Video

A key opinion leader explains how acquired TTP is diagnosed, with a focus on the use of ADAMTS13 testing.

Overview of Acquired Thrombotic Thrombocytopenic Purpura

August 13th 2021, 6:51pm

Video

X. Long Zheng, MD, PhD, gives an overview on acquired thrombotic thrombocytopenic purpura including prevalence and the typical patient presentation.

ACIP Votes to Lift Pause on J&J COVID-19 Vaccine

April 23rd 2021, 9:32pm

Article

The CDC's Advisory Committee on Immunization Practices voted to uphold the original language of the emergency use authorization for Johnson & Johnson's COVID-19 vaccination, and is possible the 1-dose vaccine could resume Saturday.

Gene Transfer Therapy Requires Further Investigation Despite Potential Approval, Review Says

April 23rd 2021, 8:17pm

Article

After a more than 35-year pursuit, the licensing of a gene therapy product for treating hemophilia may be available within 2 years.

Carfilzomib, Bortezomib Combo Shows Potential for Reducing Tumor Growth in Melanoma Cells

April 15th 2021, 3:45pm

Article

The in vitro study of melanoma cells analyzed the molecular mechanisms of the pair of proteasome inhibitors, finding that they reduced B16-F1 tumor growth.

CDC, FDA Call for Pause of J&J COVID-19 Vaccine After Safety Concerns Around Clotting

April 13th 2021, 3:18pm

Article

After cases of rare and severe blood clots led to 1 death and 1 hospitalization, the CDC and FDA will pause the use of Johnson & Johnson's (J&J) COVID-19 vaccine.